Atea Pharmaceuticals Inc. (AVIR)
NASDAQ: AVIRHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
AVIR stock chart
Technical analysisKey statistics
All statistics- Market cap
- $318.00M
- EPS (TTM)
- -$1.95
- Dividend yield
- None
- 52-week range
- 2.96 – 6.45
- Day range
- 3.80 – 4.09
- Volume / Avg
- 416.46K / 290.60K
- Beta
- —
- Shares outstanding
- 80.30M
52-week range
AVIR stock today
Shares of Atea Pharmaceuticals (AVIR) finished higher on Nov 20 at $3.96, a gain of 0.76% or $0.03 per share, versus the S&P 500's 3.70% decline. At this level, AVIR sits in the middle of its 52-week range of $2.96 to $6.45: 38.6% below the high, set on Mar 10, 2026 and 33.8% above the low. AVIR is up 10.9% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 33.3%.
Atea Pharmaceuticals has posted a net loss over the last twelve months (EPS of -$1.95), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Atea Pharmaceuticals
Company profileAtea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company also developing AT-587, that is in Phase 1 clinical trial for the treatment of chronic HEV infection.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Jean-Pierre Sommadossi Ph.D.
- Headquarters
- Boston, MA
- Employees
- 55
- IPO year
- 2020
- Website
- ateapharma.com
Financial highlights
Full financialsAtea Pharmaceuticals reported a net loss of $158.3 million, compared with a loss of $168.4 million a year earlier. Diluted earnings per share came in at -$1.94.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | $351.37M |
| Growth | — | — | — | — | +622.49% |
| Net income | $-158.35M | $-168.38M | $-135.96M | $-115.91M | $121.19M |
| EPS (diluted) | $-1.94 | $-2.00 | $-1.63 | $-1.39 | $1.37 |
Analyst forecast
ForecastConsensus (3 analysts)
buy
Avg. price target
$9.00+127.27%
- Strong buy 0
- Buy 2
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 9, 2026
- EPS actual vs est.
- $-0.40 vs $-0.51
- Surprise
- +21.57%
AVIR news
All AVIR news- Is Medpace (MEDP) Stock Outpacing Its Medical Peers This Year?NasdaqMEDP, AVIR
- Atea Q3 Loss Narrows On Lower Expenses; Hepatitis C Trial Data Due In Early 2027NasdaqAVIR, HEI.A
- Atea Pharmaceuticals, Inc. Reports Third Quarter 2026 Financial Results and Enters Credit Facility of Up to $200 MillionNasdaq
- Atea Pharma (AVIR) Q3 2026 Earnings Call TranscriptNasdaq
- Atea Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business UpdateGlobeNewswire
- Atea Secures $200 Mln Credit Facility From Hercules Capital; Shares UpNasdaqAVIR, HTGC
- Atea Pharmaceuticals to Host Third Quarter 2026 Financial Results and Business Update Conference Call on November 9, 2026GlobeNewswire
Atea Pharmaceuticals peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| LRMRLarimar Therapeutics Inc. | 3.14 | -2.48% | $328.55M | vs AVIR |
| INOInovio Pharmaceuticals Inc. | 1.76 | +2.92% | $329.66M | vs AVIR |
| MPLTMapLight Therapeutics Inc. | 5.94 | -7.48% | $330.12M | vs AVIR |
| SPRYARS Pharmaceuticals Inc. | 2.96 | -11.90% | $297.56M | vs AVIR |
| EVMNEvommune Inc. | 7.04 | -2.76% | $291.10M | vs AVIR |
| CTNMContineum Therapeutics Inc. Class A | 8.68 | -3.98% | $340.83M | vs AVIR |
| BNTCBenitec Biopharma Inc. | 7.92 | -2.76% | $285.88M | vs AVIR |
| GLSIGreenwich LifeSciences Inc. | 19.25 | -2.73% | $282.56M | vs AVIR |
Indexes, lists and sector
Atea Pharmaceuticals stock FAQ
What is Atea Pharmaceuticals's stock price today?
AVIR last traded at $3.96 as of Nov 20, 4:00 PM EST, up 0.76% on the day. Prices are delayed at least 15 minutes.
Who is Atea Pharmaceuticals's CEO?
Dr. Jean-Pierre Sommadossi Ph.D. is the chief executive officer of Atea Pharmaceuticals Inc., which has about 55 employees.
What is the AVIR 52-week high?
The 52-week high for AVIR is $6.45 and the 52-week low is $2.96. The stock is currently 38.6% below its high.